Wall Street analysts expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to report $361.96 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Integra Lifesciences’ earnings, with the lowest sales estimate coming in at $359.03 million and the highest estimate coming in at $370.70 million. Integra Lifesciences posted sales of $357.08 million in the same quarter last year, which would indicate a positive year over year growth rate of 1.4%. The company is scheduled to issue its next quarterly earnings report on Wednesday, April 24th.
According to Zacks, analysts expect that Integra Lifesciences will report full-year sales of $1.52 billion for the current year. For the next fiscal year, analysts anticipate that the business will post sales of $1.60 billion, with estimates ranging from $1.59 billion to $1.61 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, February 21st. The life sciences company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.03. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. The firm had revenue of $383.30 million for the quarter, compared to analyst estimates of $382.33 million. During the same quarter in the previous year, the firm posted $0.64 earnings per share. The business’s revenue was up 4.0% on a year-over-year basis.
In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 30,128 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the sale, the insider now directly owns 143,384 shares of the company’s stock, valued at $8,038,107.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its position in Integra Lifesciences by 5.2% during the third quarter. FMR LLC now owns 11,650,977 shares of the life sciences company’s stock worth $767,451,000 after acquiring an additional 572,857 shares in the last quarter. Capital Research Global Investors raised its position in Integra Lifesciences by 4.3% during the third quarter. Capital Research Global Investors now owns 10,186,218 shares of the life sciences company’s stock worth $670,966,000 after acquiring an additional 423,324 shares in the last quarter. BlackRock Inc. raised its position in Integra Lifesciences by 3.2% during the fourth quarter. BlackRock Inc. now owns 6,730,304 shares of the life sciences company’s stock worth $303,536,000 after acquiring an additional 210,960 shares in the last quarter. Janus Henderson Group PLC raised its position in Integra Lifesciences by 2.2% during the third quarter. Janus Henderson Group PLC now owns 2,009,131 shares of the life sciences company’s stock worth $132,341,000 after acquiring an additional 42,790 shares in the last quarter. Finally, Clearbridge Investments LLC raised its position in Integra Lifesciences by 7.9% during the third quarter. Clearbridge Investments LLC now owns 1,810,641 shares of the life sciences company’s stock worth $119,267,000 after acquiring an additional 132,805 shares in the last quarter. 83.11% of the stock is currently owned by hedge funds and other institutional investors.
IART traded down $0.13 during trading on Tuesday, reaching $56.01. The company had a trading volume of 821,927 shares, compared to its average volume of 488,574. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.88 and a current ratio of 2.95. Integra Lifesciences has a 12 month low of $42.14 and a 12 month high of $67.50. The firm has a market cap of $4.78 billion, a P/E ratio of 23.14, a PEG ratio of 1.63 and a beta of 0.96.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.